[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:pleural-malignant-mesothelioma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":111,"states":116},"Pleural Malignant Mesothelioma",16,14,[8,16,23,29,35,42,48,54,60,66,72,78,84,90,96,103],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05647265","Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:24.721169Z","2026-05-05T02:43:28.559849Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03760575","Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)",[20],"Phase 1","2026-08-26T02:17:30.961790Z","2026-05-05T02:43:27.979517Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07126509","Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma",[],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.111042Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",[20],"2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.679197Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT05584670","A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors",[39],"Phase 1\u002FPhase 2","2026-08-26T02:18:35.425468Z","2026-05-05T02:43:29.645288Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06756035","CT-95 in Advanced Cancers Associated With Mesothelin Expression",[20],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:28.867277Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06535607","Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced\u002FMetastatic Solid Tumors",[12],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:28.283401Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05107674","A Study of NX-1607 in Adults With Advanced Malignancies",[20],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:28.117316Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06362369","A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",[39],"2026-08-26T02:19:22.562392Z","2026-05-05T02:43:27.135162Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05841563","Clinical Trial of PM54 in Advanced Solid Tumors Patients.",[20],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:26.706220Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05086692","A Beta-only IL-2 ImmunoTherapY Study",[39],"2026-08-26T02:18:31.164304Z","2026-05-05T02:35:31.708594Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06037941","Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma",[],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.121856Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT03683680","Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers",[],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:27.633582Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT00242723","Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining",[],"2026-08-26T02:17:18.747857Z","2026-07-24T01:27:14.927794Z",{"nct_id":97,"title":98,"phases":99,"status":100,"updated_at":101,"content_modified":102},"NCT05425576","OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:11.740957Z","2026-05-05T02:43:29.195809Z",{"nct_id":104,"title":105,"phases":106,"status":108,"updated_at":109,"content_modified":110},"NCT06097728","MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",[107],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T02:09:46.172607Z","2026-05-05T02:43:27.953969Z",[112],{"biomarker":113,"count":114,"slug":115},"MSI1 Gene",3,"msi1-gene",[117,121,125,129,133,136,139,143,146,149,152,155],{"state":118,"count":119,"slug":120},"Texas",9,"texas",{"state":122,"count":123,"slug":124},"Pennsylvania",7,"pennsylvania",{"state":126,"count":127,"slug":128},"California",6,"california",{"state":130,"count":131,"slug":132},"Florida",5,"florida",{"state":134,"count":131,"slug":135},"Illinois","illinois",{"state":137,"count":131,"slug":138},"New York","new-york",{"state":140,"count":141,"slug":142},"Colorado",4,"colorado",{"state":144,"count":141,"slug":145},"New Jersey","new-jersey",{"state":147,"count":141,"slug":148},"Washington","washington",{"state":150,"count":114,"slug":151},"Maryland","maryland",{"state":153,"count":114,"slug":154},"Michigan","michigan",{"state":156,"count":114,"slug":157},"Virginia","virginia"]